Leaps by Bayer

We released a new report from our Breakthrough Study, surveying US attitudes toward innovation. One of our findings: Americans who identify as ‘progressive’ have a more positive view on new genomic techniques vs. traditionalists’ opinion on #NGTs. Read on: leaps.bayer.com/breakthroughst…

How do we measure #impact beyond #ROI? With WALY: Wellbeing Adjusted Lifeyears — a new way to quantify human & planetary #wellbeing. 🎥 Watch the video to dive into the #math and learn about the #formula behind the framework.

As we understand Alzheimer’s better, one truth stands out: The earlier we detect it, the more we can do. Here is a look at how we got here, with @PhylFerrell, Dr. Greg Cooper, Jeff Burns, & @Wilcock_v2: forbes.com/sites/juergene…

🧠 Alzheimer’s impacts more than just the diagnosed patient. Loved ones often become caregivers – managing daily needs, stress, and hard choices. First symptoms are easy to miss. But early detection matters. ➡️ Swipe the carousel to learn more.

People. Planet. Profit. 📐 Financial returns and societal impact don’t have to be a trade-off – says Juergen Eckhardt, Head of Leaps by Bayer. But to align them, we need a way to measure what really matters.

How do you measure impact? At Leaps by Bayer, we partnered with @Happi_Research to create #WALY – Wellbeing Adjusted Lifeyears. It quantifies how investments affect human & planetary #wellbeing — beyond profit. Not all impact shows up on a balance sheet. 🎥 Watch the video

The next global health crisis might be already here and it’s drug-resistant. 👇 See the urgency in #AMR in one graphic.

How do you measure impact? At Leaps by Bayer, we teamed up with @Happi_Research to create #WALY – Wellbeing Adjusted Lifeyears. It’s a new way to quantify human & planetary #wellbeing beyond profit. 🎥 Curious? Watch the full video on our YouTube.

How do you measure impact beyond profit? At Leaps by Bayer, we co-created a new impact measurement framework with @Happi_Research called #WALY - a new way to track what really matters: human & planetary wellbeing. 🎥 Curious? Watch the video.

Antibiotic-resistant infections are the 2nd leading cause of death in cancer patients. We need policy reform and incentives to revive antibiotic innovation and protect modern medicine. 📖 Read more in the @Forbes op-ed by Juergen Eckhardt ➡️ forbes.com/sites/juergene…

Just as cancer therapies reach new heights, a silent threat is pulling us back: antibiotic-resistant infections. New research shows cancer patients are 1.5x more likely to develop drug-resistant infections. Read Juergen Eckhardt’s @Forbes op-ed ➡️ forbes.com/sites/juergene…

It started with a Nobel Prize. Now, #CRISPR could transform how we fight disease and grow food. Jennifer Doudna shares her vision with Leaps by Bayer’s Juergen Eckhardt: forbes.com/sites/juergene… __ The picture was taken at Liberty Science Center's Genius Gala by Nicole Craine.

Looking to fast-track your #AgTech journey? Unpack lessons from decades of development from experts in #AgTech #innovation in the Ag Playbook. It’s a must-read for every pioneer, going from early discovery all the way to successful field trials.🌾 leaps.bayer.com/AgPlaybook.pdf 📚

Innovative targeted therapies are needed for autoimmune disorders. @Mozart_tx, Sudo Bioscience and @nuvigtx are responding with pioneering approaches and new technologies!

Autoimmune diseases affect 320M+ people globally. In @Forbes, Juergen Eckhardt highlights 4 innovations – from CAR-T alternatives to inverse RNA vaccines – that aim to retrain, not just suppress, the immune system. 👉 forbes.com/sites/juergene…

#AutoimmuneDiseases impact millions – and current treatments often just manage symptoms, not the root cause. At Leaps, we’re backing innovators aiming to retrain the immune system. What breakthroughs do you think will drive real change? 💡

How do different generations’ perceptions of the use of AI in healthcare in America vary? Find answers in our snapshot report, “How Society Feels About Breakthrough Science – In the USA”. Learn more: leaps.bayer.com/breakthroughst…

Here is a quick look at how PROTACs work in oncology, Alzheimer’s and more, as @ArvinasInc and @OerthBio develop the tech further. Follow us to get more exciting updates!

💡 Our VP of Venture Investments Agriculture, Derek Norman, shared a great reflection on the #agtech market in his first LinkedIn pulse article. Read the article to learn his top 4 key take-aways after last months' World Agri-Tech. 🌱 View more: spr.ly/6018F0lBi

🥳 Exciting News: @OerthBio published its science in @NatureComms, proving that it can design protein degraders with precision, taking PROTACs from fighting cancer to protecting crops. 📄 Read the seminal study here: nature.com/articles/s4200…